President of MaxCyte Maher Masoud Buys More Stock
Craig-Hallum Maintains MaxCyte(MXCT.US) With Buy Rating
Craig-Hallum analyst Matt Hewitt maintains $MaxCyte(MXCT.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 43.9% and a total average return of -3.8% over the past ye
Insider Buying: President and CEO Maher Masoud Acquires 100,000 Shares of MaxCyte Inc (MXCT)
MaxCyte(MXCT.US) Officer Buys US$489.07K in Common Stock
$MaxCyte(MXCT.US)$ Officer Masoud Maher purchased 100K shares of common stock on Jun 7, 10, 2024 at an average price of $4.891 for a total value of $489.07K.Source: Announcement What is statement of c
Maxcyte Insider Bought Shares Worth $489,066, According to a Recent SEC Filing
Maher Masoud, Director, President and CEO, on June 07, 2024, executed a purchase for 100,000 shares in Maxcyte (MXCT) for $489,066. Following the Form 4 filing with the SEC, Masoud has control over a
MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
ROCKVILLE, Md., May 29, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
Express News | MaxCyte Signs License Agreement With Legend Biotech, Under Which Legend Obtains Non-Exclusive Worldwide License To Use MaxCyte's Flow Electroporation And ExPERT Platform; MaxCyte Eligible For Fees And Miletones
Express News | MaxCyte Inc - Upon Successful Commercialization, Is Eligible to Receive Licensing Fees and Royalties on Net Sales of Licensed Products
Express News | MaxCyte Inc - Will Be Eligible to Receive Annual Licensing Fees and Milestones From Legend Biotech During Clinical Development
Express News | MaxCyte Inc - Under Terms, Legend Biotech Obtains a Non-Exclusive Worldwide License to Use Co's Flow Electroporation Technology and Expert Platform
Express News | MaxCyte, Inc. MaxCyte, Inc. - Mxcr - Signing of Strategic Platform License
Express News | MaxCyte Signs Strategic Platform License Agreement With Legend Biotech to Accelerate Cell Therapy Discovery and Development
BlackRock Increases Stake in MaxCyte, Inc.
BlackRock Acquires Major Stake in MaxCyte
Vicore Expands and Strengthens Its Board of Directors
STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of
MaxCyte, Inc. (NASDAQ:MXCT) Q1 2024 Earnings Call Transcript
Earnings Call Summary | MaxCyte(MXCT.US) Q1 2024 Earnings Conference
The following is a summary of the MaxCyte, Inc. (MXCT) Q1 2024 Earnings Call Transcript:Financial Performance:MaxCyte reported a total revenue of $11.3 million in Q1 2024, a rise of 32% from the $8.6
MaxCyte, Inc. (MXCT) Q1 2024 Earnings Call Transcript
MaxCyte, Inc. (MXCT) Q1 2024 Earnings Call Transcript
MaxCyte Shares Rise Sharply After Q1 Results Beat
MaxCyte (MXCT) shares were up more than 20% in recent Wednesday trading after the company reported better-than-expected Q1 results in the previous day. The company reported late Tuesday a Q1 loss of $
MaxCyte Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
MaxCyte Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
No Data